Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson INVOKANA / INVOKAMET [reported separately through by Quarter
INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide sales ($M) ($M)
Johnson & Johnson INVOKANA / INVOKAMET [reported separately through: $91M in Q4 2022, down 24.2% from a year earlier. That is the lowest of the 25 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2022 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2023-02-16) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2022 | Jan 1, 2023 | 91 | -24.2% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2022 | Oct 2, 2022 | 109 | -18.0% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 120 | -25.0% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2022 | Apr 3, 2022 | 128 | -14.7% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Jan 2, 2022 | 120 | -44.7% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 133 | -40.6% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 160 | -10.6% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 150 | -14.3% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 217 | +22.6% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 224 | +25.1% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 179 | +1.1% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 175 | -13.4% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 177 | -22.4% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 179 | -5.8% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 177 | -17.7% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 202 | -18.5% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 228 | -14.6% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 190 | -28.3% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 215 | -27.1% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 248 | -12.7% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 267 | -28.0% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 265 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 295 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 284 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 371 | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up INVOKANA / INVOKAMET [reported separately through
- INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — U.S. sales ($M)29 · Q4 2022
- INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — International sales ($M)62 · Q4 2022
- INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide reported growth YoY (%)-24.1% · Q4 2022
- INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide operational (constant-currency) growth YoY (%)-19.6% · Q4 2022
Cite this data
StockData. (2026). Johnson & Johnson INVOKANA / INVOKAMET [reported separately through ($M), quarterly Q4 2016–Q4 2022 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-invokana
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.